Close Menu

NEW YORK (GenomeWeb) — BioMérieux today announced that it has received 510(k) clearance from the US Food and Drug Administration for the expanded use of its Vidas BRAHMS PCT assay for managing sepsis patients with elevated risk of mortality. 

The assay, which runs on BioMérieux's fully automated Vidas instrument, is designed to measure changes in blood levels of procalcitonin — a peptide precursor of calcitonin and a marker of inflammatory response — to differentiate bacterial infections from viral ones.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.